Anavex Life Sciences Crecimiento futuro
Future controles de criterios 0/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Anavex Life Sciences de 19.2% y 99.3% respectivamente, mientras que el BPA crecerá en un 22.4% al año.
Información clave
19.2%
Tasa de crecimiento de los beneficios
22.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 24.8% |
Tasa de crecimiento de los ingresos | 99.3% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 10 May 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Anavex shares up 65% in morning trading continuing hot streak
Feb 04Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum
Jan 05Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Jan 01Anavex Life Sciences EPS beats by $0.06
Dec 28Anavex's blarcamesine successful in mid-stage rett syndrome study
Dec 15Additional U.S. patents for Anavex Life Sciences' blarcamesine
Nov 30Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
9/30/2026 | 3 | -35 | N/A | N/A | 1 |
9/30/2025 | N/A | -57 | N/A | N/A | 2 |
9/30/2024 | N/A | -44 | N/A | N/A | 2 |
3/31/2024 | N/A | -41 | -32 | -32 | N/A |
12/31/2023 | N/A | -43 | -29 | -29 | N/A |
9/30/2023 | N/A | -48 | -28 | -28 | N/A |
6/30/2023 | N/A | -52 | -26 | -26 | N/A |
3/31/2023 | N/A | -53 | -25 | -25 | N/A |
12/31/2022 | N/A | -50 | -27 | -27 | N/A |
9/30/2022 | N/A | -48 | -24 | -24 | N/A |
6/30/2022 | N/A | -45 | -28 | -28 | N/A |
3/31/2022 | N/A | -43 | -28 | -28 | N/A |
12/31/2021 | N/A | -41 | -26 | -26 | N/A |
9/30/2021 | N/A | -38 | -30 | -30 | N/A |
6/30/2021 | N/A | -32 | -29 | -29 | N/A |
3/31/2021 | N/A | -28 | -25 | -25 | N/A |
12/31/2020 | N/A | -28 | -23 | -23 | N/A |
9/30/2020 | N/A | -26 | -21 | -21 | N/A |
6/30/2020 | N/A | -26 | -18 | -18 | N/A |
3/31/2020 | N/A | -26 | -21 | -21 | N/A |
12/31/2019 | N/A | -26 | -20 | -20 | N/A |
9/30/2019 | N/A | -26 | -19 | -19 | N/A |
6/30/2019 | N/A | -26 | -20 | -20 | N/A |
3/31/2019 | N/A | -23 | -15 | -15 | N/A |
12/31/2018 | N/A | -20 | -13 | -13 | N/A |
9/30/2018 | N/A | -17 | -13 | -13 | N/A |
6/30/2018 | N/A | -17 | -11 | -11 | N/A |
3/31/2018 | N/A | -18 | -12 | -12 | N/A |
12/31/2017 | N/A | -14 | N/A | -9 | N/A |
9/30/2017 | N/A | -13 | N/A | -9 | N/A |
6/30/2017 | N/A | -15 | N/A | -9 | N/A |
3/31/2017 | N/A | -13 | N/A | -8 | N/A |
12/31/2016 | N/A | -14 | N/A | -9 | N/A |
9/30/2016 | N/A | -15 | N/A | -9 | N/A |
6/30/2016 | N/A | -14 | N/A | -9 | N/A |
3/31/2016 | N/A | -16 | N/A | -8 | N/A |
12/31/2015 | N/A | -15 | N/A | -7 | N/A |
9/30/2015 | N/A | -12 | N/A | -4 | N/A |
6/30/2015 | N/A | -15 | N/A | -4 | N/A |
3/31/2015 | N/A | -12 | N/A | -3 | N/A |
12/31/2014 | N/A | -11 | N/A | -3 | N/A |
9/30/2014 | N/A | -10 | N/A | -3 | N/A |
6/30/2014 | N/A | -5 | N/A | -2 | N/A |
3/31/2014 | N/A | -4 | N/A | -1 | N/A |
12/31/2013 | N/A | -3 | N/A | -1 | N/A |
9/30/2013 | N/A | -4 | N/A | -1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que AVXL siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que AVXL siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que AVXL siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que AVXL no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que AVXL no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AVXL se prevé que sea elevada dentro de 3 años.